U.S. FDA set to reorganize its food division starting October
May 30 (Reuters) -The U.S. Food and Drug Administration(FDA) said on Thursday it plans to restructure its food division starting in October helping it to oversee human food supply chains and agricultural products more efficiently.
The regulatory body had come under fire over its slow response to the infant formula shortage in 2022.
WHY IT'S IMPORTANT
The FDA said the reorganization will enable it to be more efficient and agile while regulating the industry.
The reorganization will lead to the creation of a unified Human Foods Program (HFP), the adoption of a new model for the FDA's field operations among other changes.
The HFP will take over the roles of the Center for Food Safety and Applied Nutrition and the Office of Food Policy and Response, along with key functions from the Office of Regulatory Affairs, which will be renamed to the Office of Inspections and Investigations.
KEY QUOTE
"This is a distinctive moment for the FDA... We are a step closer to seeing the largest reorganization of the agency in recent history come to life this fall," said FDA Commissioner Robert M. Califf.
CONTEXT
The FDA announced the HFP's establishment last year after being criticizedfor not providing enough resources for its food-related programs in wake of infant formula shortage.
The changes were made in line with the recommendations made in 2022by the Reagan-Udall Foundation, an organization in part funded by the health regulator, that assessed how the agency could shore up its food operations.
The agency, in September last year, appointedJames Jones, an EPA veteran, as its deputy commissioner for human foods, and put him in charge of setting up the human foods program.
Reporting by Puyaan Singh in Bengaluru; Editing by Tasim Zahid
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
